Barinthus Biotherapeutics plc. (NASDAQ: BRNS)

Barinthus Biotherapeutics plc is a clinical stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases within the immunology and inflammation space.

The company’s proprietary SNAP TI platform is designed to promote immune tolerance by guiding patient T cells to reduce inflammation and restore natural immune non responsiveness to healthy tissue.

Its lead candidate VTP 1000 is designed to restore immune non responsiveness to gluten in patients with celiac disease and is currently being assessed in a Phase 1 clinical trial.

Based on encouraging preclinical data the company believes the SNAP TI platform has the potential to impact multiple other immunology and inflammation indications.

Barinthus Biotherapeutics plc generates revenue primarily through licensing agreements and potential milestone payments from collaborators.

The company has an agreement with Oxford University Innovation that includes an upfront fee and low single digit royalties on net sales of any product using the licensed technology.

Barinthus Biotherapeutics plc also holds a license with the National Institutes of Health that provides an upfront fee and low single digit royalties on net sales and includes milestone payments of up to several million dollars.

In addition the company seeks partnership arrangements for its VTP 300 hepatitis B candidate and other legacy assets which could yield further licensing income and shared development costs.

Barinthus Biotherapeutics plc positions itself as a developer of antigen specific immune tolerance therapies that aim to correct T cell imbalances underlying autoimmune and inflammatory diseases.

Its SNAP TI platform uses synthetic self assembling nanoparticles to improve manufacturability of multiple antigen compositions and allows administration by intramuscular or subcutaneous routes.

The platform also incorporates an immunomodulator intended to increase regulatory T cell activity and decrease effector T cell responses thereby improving the Treg Teff ratio.

While other companies pursue broad immunosuppression or antigen nonspecific approaches Barinthus Biotherapeutics plc differentiates itself by focusing on highly disease specific treatments that may reduce the need for lifelong therapy.

The company’s track record of executing development activities and its scientific expertise in T cell immunology give it a competitive advantage in advancing novel tolerogenic candidates.

Barinthus Biotherapeutics plc targets patients suffering from celiac disease and chronic hepatitis B infection as the primary recipients of its therapeutic candidates.

The company also engages with collaboration partners such as Arbutus Biopharma the National Institutes of Health and Oxford University Innovation to advance its programs and secure licensing revenue.